Citigroup Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has upgraded Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Buy and raised the price target from $40 to $57.
May 22, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Joanne Wuensch has upgraded Tandem Diabetes Care from Neutral to Buy and raised the price target from $40 to $57.
The upgrade from Neutral to Buy and the significant increase in the price target from $40 to $57 by a reputable analyst at Citigroup is likely to positively impact the stock price of Tandem Diabetes Care in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100